Three ( @ % ) of @ patients in the tofacitinib @ mg group , ten ( @ % ) of @ in the tofacitinib @ mg group , @ ( @ % ) of @ in the etanercept group , and four ( @ % ) of @ patients in the placebo group discontinued their assigned treatment because of adverse events .